Paxlovidi kohta
Jäta sõnum
22. detsembril 2021 andis USA Toidu- ja Ravimiamet (FDA) Pfizerile erakorralise kasutusloa suukaudse viirusevastase ravimi Paxlovid jaoks COVID-i raviks-19. Paxlovid (nirmatrelviir/PF-07321332 ja ritonaviir) on nüüd lubatud 2019. aasta kerge kuni mõõduka koronaviirushaiguse (COVID-19) raviks 12-aastastel ja vanematel täiskasvanutel ja lastel, kes kaaluvad vähemalt 40 kg ja kellel on positiivne SARS-CoV- 2 test, kellel on suur risk progresseeruda raskesse COVID-19, sealhulgas haiglasse või surra.
Jianfeng is a research-driven pharmaceutical company. Established in 2011, we have more than 10 years experience in the pharmacy filed. In the principle of "Quality Oriented", Jianfeng passed the certification of ISO9001:2008 Quality Management System. Our products meet USP, EP standards and are exported to US, Germany, Canada, Japan, etc. For better production, Jianfeng has set up advanced labs and factories.
"Honesty, practicality, innovation, development" is our value. Jianfeng would like to cooperate with you with high quality products and competitive price.
